NovaBay Pharmaceuticals to Present at the Annual OneMedPlace Finance Forum
EMERYVILLE, CA--(Marketwire - January 7, 2010) - NovaBay Pharmaceuticals, Inc. (NYSE Amex: NBY), a clinical stage biopharmaceutical company developing a new class of
anti-infectives for treating multi-drug resistant pathogens, today
announced that Ron Najafi, Ph.D., Chairman and Chief Executive Officer,
will deliver a corporate presentation at the Annual OneMedPlace Finance
Forum on Tuesday, Jan. 12 in San Francisco.
Dr. Najafi's presentation will take place at 10 a.m. PST in the Cypress
Room at the Sir Francis Drake Hotel. His presentation will provide a
corporate overview and highlight NovaBay's clinical progress in its
internal programs, as well as in its partnered programs with Alcon (NYSE: ACL) and Galderma.
NovaBay Pharmaceuticals is a clinical stage biopharmaceutical company
focused on developing its proprietary and patented Aganocide compounds,
which are novel, synthetic anti-infective product candidates with
equivalent activity to the active antimicrobial molecules generated within
white blood cells. NovaBay's Aganocides are being developed to treat and
prevent a wide range of infections without causing bacterial resistance.
NovaBay has internal development programs aimed at addressing hospital and
respiratory infections. The company has a license and research
collaboration agreement with Alcon, Inc. for use of its Aganocide compounds
to treat eye, ear and sinus infections as well as for contact lens care.
NovaBay has also entered into an agreement with Galderma S.A. to develop
and commercialize Aganocides in acne, impetigo and other dermatological
indications. NovaBay™ and Aganocide® are trademarks of NovaBay
Pharmaceuticals, Inc. For more information on NovaBay, visit: